BHVN · NYSE · Healthcare · Biotechnology

Biohaven

—Past month
Price unavailable
  • 52W range7.48–18.57
  • Market cap2.15B

Latest news

Loading...

About

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is i...

biohaven.com